CAMP
CAMP4 THERAPEUTICS CORPORATION
4.20
-0.13 (-3.00%)
52w low 2.90
7.75 high
26.8% of range
Open
4.41
High
4.41
Low
4.14
Prev Close
4.33
Volume
95.22K
Avg Vol 3M
257.63K
Market Cap
263.57M
Currency
USD
6 Month Trend
—
C--
Chg--
Gap--
Vol--
×avg--
σ--
SMA20--
SMA50--
SMA200--
RSI--
SPY--
DD--
Bench--
Sig--
Hist--
pinned · Esc to release
hover · click to pin · ← → step · drag to zoom · shift-drag to measure
—Context
- Move across the chart.
Company
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| Employees | 48 |
| Web | site ↗ |
Performance
1D
-3.00%
5D
+12.30%
1M
+14.75%
3M
-7.28%
6M
-6.67%
YTD
-31.48%
1Y
+1.69%
2Y
-60.04%
3Y
--
5Y
--
MAX
-60.49%
Valuation
| P/E Trailing | -- |
| P/E Forward | -5.24x |
| Price / Book | 2.46x |
| Price / Sales | 49.54x |
| EV / EBITDA | -3.02x |
| EPS Trailing | -2.11 |
| Dividend Yield | 0.00% |
| Beta | 0.28 |
Profitability
| Gross Margin | 0.00% |
| Operating Margin | -991.77% |
| Net Margin | 0.00% |
| Return on Equity | -146.12% |
| Return on Assets | -29.92% |
| Revenue Growth | +138.90% |
| Debt / Equity | 0.06x |
| Current Ratio | 6.42x |
Business
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.